Although data from oral cancer-specific immunotherapy trials is not yet available, ongoing clinical trials conducted with lung cancer patients have found several responders with lack of PD-L1 expression, as well as responders with low mutation burdens and no history of smoking abuse. The gene discussed is CD274; the disease is lung carcinoma.